Heart specific PGC-1α deletion identifies metabolome of cardiac restricted metabolic heart failure

Olli Kärkkäinen1, Tomi Tuomainen2, Maija Mutikainen2

  • 1Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1 C, Kuopio, Finland.

Insights

Cardiac-specific PGC-1α knockout in mice causes heart failure by altering heart metabolism. These metabolic changes were confined to the heart, not affecting other tissues or circulation.

Area of Science:

  • Cardiovascular Biology
  • Metabolomics
  • Molecular Cardiology

Background:

  • Heart failure (HF) involves significant metabolic alterations, but the origin of these changes (cardiomyocyte-specific vs. systemic) remains unclear.
  • Understanding the interplay between cardiomyocyte metabolism and systemic metabolic health is crucial for developing effective HF therapies.

Purpose of the Study:

  • To investigate if cardiac-restricted metabolic changes, mimicking HF, induce systemic metabolic alterations.
  • To characterize metabolite profiles in the heart, circulation, and peripheral tissues following targeted cardiac metabolic disruption.

Main Methods:

  • Generation of cardiac-specific PGC-1α knockout (KO) mice to induce metabolic dysregulation.
  • Non-targeted LC-MS metabolite profiling of heart, plasma, liver, and skeletal muscle.
  • Assessment of cardiac function and structural changes.

Main Results:

  • Cardiac-specific PGC-1α KO mice developed progressive cardiomyopathy, cardiac dilatation, and fatal HF.
  • KO cardiomyocytes exhibited suppressed glucose and fatty acid oxidation, and blunted anaerobic metabolism.
  • KO hearts showed distinct metabolic profiles with altered energy metabolism, phospholipid metabolism, amino acid metabolism, and oxidative stress signaling, correlating with cardiac function.

Conclusions:

  • Heart-specific PGC-1α deficiency leads to metabolic, functional, and structural abnormalities, resulting in dilated cardiomyopathy and HF.
  • Metabolic alterations were confined to the cardiac tissue, suggesting cardiomyocyte metabolic remodeling alone is insufficient to drive body-wide metabolic changes seen in HF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Anatomy of the Heart01:27

Anatomy of the Heart

The human heart is made up of three layers of tissue that are surrounded by the pericardium, a membrane that protects and confines the heart. The outermost layer, closest to the pericardium, is the epicardium. The pericardial cavity separates the pericardium from the epicardium. Beneath the epicardium is the myocardium, the middle layer, and the endocardium, the innermost layer. There are four chambers of the heart: the right atrium, the right ventricle, the left atrium, and the left ventricle.
120.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990